Originally published as JCO Early Release 10.1200/JCO.2004.10.052 on July 12 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schey, S.A. Articles by Dalgleish, A.G. Search for Related Content PubMed PubMed Citation Articles by Schey, S.A. Articles by Dalgleish, A.G. Related Articles Related Editorial Social Bookmarking                            What's this?

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

From the Guy’s and St Thomas’ Trust, Department of Haematology, Thomas Guy House; Department of Cellular and Molecular Medicine, St George’s Hospital, London, United Kingdom; and Celgene Corp, San Diego, CA

Address reprint requests to S.A. Schey, MD, Guy’s and St Thomas’ Trust, Department of Haematology, Thomas Guy House, London SE1 9RT, United Kingdom; e-mail: steve.schey{at}gstt.sthames.nhs.uk

PURPOSE: To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.

PATIENTS AND METHODS: Twenty-four relapsed or refractory patients were treated with a dose-escalating regimen of oral CC-4047. Clinical responses and adverse effects were identified, and peripheral T-cell subsets, serum cytokines, and proangiogenic factors were evaluated.

RESULTS: CC-4047 was tolerated with no serious nonhematologic adverse events. All patients were eligible for analysis. Toxicity criteria during the initial 4 weeks of study were used to define the maximum-tolerated dose (MTD). During this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew because of progressive disease (PD), and three patients discontinued with neutropenia. Nineteen of 24 patients continued on treatment beyond 4 weeks to PD or development of a serious adverse event. Three further patients developed a DVT at 4, 9, and 11 months. Treatment resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered complete remission. The MTD was 2 mg/d. All patients showed increased CD45RO expression on CD4⁺ and CD8⁺ cells, with a concomitant decrease in CD45RA⁺ cells. CC-4047 treatment was associated with significantly increased serum interleukin (IL)-2 receptor and IL-12 levels, which is consistent with activation of T cells and monocytes and macrophages.

CONCLUSION: This study demonstrates the safety and efficacy of CC-4047. The MTD of CC-4047 orally was 2 mg/d. This is the first report demonstrating in vivo T-cell costimulation by this class of compound, supporting a potential role for CC-4047 as an immunostimulatory adjuvant treatment.

Support for this study was provided by Celgene Corp, Warren, NJ.

Preliminary data presented at the 31st International Society of Haematology, Montreal, Canada, July 2002.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
  Paul Richardson and Kenneth Anderson
  JCO 2004 22: 3212-3214 [Full Text]

This article has been cited by other articles:

				M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784. [Abstract] [Full Text] [PDF]

				S. Shalapour, A. Zelmer, M. Pfau, E. Moderegger, C. Costa-Blechschmidt, F. K.H. van Landeghem, T. Taube, I. Fichtner, C. Buhrer, G. Henze, et al. The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo. Clin. Cancer Res., September 15, 2006; 12(18): 5526 - 5532. [Abstract] [Full Text] [PDF]

				N. W. C. J. van de Donk, N. Kroger, U. Hegenbart, P. Corradini, J. F. S. Miguel, H. Goldschmidt, J. A. Perez-Simon, M. Zijlmans, R. A. Raymakers, V. Montefusco, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma Blood, April 15, 2006; 107(8): 3415 - 3416. [Full Text] [PDF]

				G. Anderson, M. Gries, N. Kurihara, T. Honjo, J. Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Y. Mapara, D. Stirling, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 Blood, April 15, 2006; 107(8): 3098 - 3105. [Abstract] [Full Text] [PDF]

				S. K Maier and J. M Hammond Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplastic Syndrome Ann. Pharmacother., February 1, 2006; 40(2): 286 - 289. [Abstract] [Full Text] [PDF]

				J. A. Zonder Thrombotic Complications of Myeloma Therapy Hematology, January 1, 2006; 2006(1): 348 - 355. [Abstract] [Full Text] [PDF]

				G. Saunders Overview of drug therapy for multiple myeloma Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100. [Abstract] [PDF]

				K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]

				P. Richardson and K. Anderson Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma J. Clin. Oncol., August 15, 2004; 22(16): 3212 - 3214. [Full Text] [PDF]